The trial performed with NXCTCL's patent-pending ProTrans, is divided into two parts, the first part being a doseescalation
phase with 3 + 3 + 3 patients being treated with either a; low, medium or high dose of ProTrans. Now
that all patients in the low-dose-cohort have been treated and after the 1-month follow-up is completed we can
start inclusion of patients in the medium-dose-cohort. The treatment and follow-up procedure are the same for the
middle-dose-cohort and high-dose-cohort.

The second part of the trial is a randomized, double-blind, placebo-controlled trial in which 10 patients receive
ProTrans and 5 patients receive placebo, a total of 15 patients. In total 24 patients will be treated with ProTrans, 9
in the dose escalation part and another 15 in the placebo-controlled part. The primary safety endpoint is drug safety
and the primary efficacy endpoint is the change in insulin production after 1 year.

The clinical trial is conducted by the Karolinska Trial Alliance and headed by Professor Per-Ola Carlsson from Uppsala
University, who is the principal investigator for the trial. The Data Safety Monitoring Board for the trial consists of
Professors Ulf Smith and Anders Fasth from the University of Gothenburg, and Åke Lernmark from Lund University.

This information is the information that NextCell Pharma AB is required to disclose under the EU Market Abuse
Regulation. The information was provided by the below contact person for publication on February 22th, 2018.

For more information about NextCell Pharma AB, please contact: Mathias Svahn, CEO Leo Groenewegen, CFO Phone: 08-735 5595 E-mail: info@nextcellpharma.com www.nextcellpharma.com (http://file//hm.local/sedermera.se/gemensam/Corp/Externa/NextCell Pharma/KOM/Pressmeddelanden/170713 - Första dag för handel/www.nextcellpharma.com)